Laumas Sandeep
Transaction: 05/14/2026
BUY
Change
+47,941
Price
Not reported
Filing
07/28/2026
Type
BUY
Unicycive Therapeutics, Inc.
UNCY • Biotechnology
$5.16
▼ -0.14 (-2.64%)
Current price
EarningsLatest report: Jun 30, 2026
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$1.39B
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0Healthy liquidity · 2.59Negative growth trendWeak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:23 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$5.16
Change-2.64%
Shares Out269.17M
Market Cap$1.39B
Enterprise Value$1.33B
52W Range3.71 - 8.74
Beta1.78
P/E-39.43
P/B26.07
P/FCF-49.88
EV/EBITDA-34.32
EV/FCF-47.69
Price$5.16
Change-2.64%
Shares Out269.17M
Market Cap$1.39B
Enterprise Value$1.33B
52W Range3.71 - 8.74
Beta1.78
P/E-39.43
P/B26.07
P/FCF-49.88
EV/EBITDA-34.32
EV/FCF-47.69
Earnings Yield-2.54%
FCF Yield-2.00%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.00
Current Ratio2.59
Quick Ratio2.59
Target$22.00
Target Upside326.36%
Target Median$22.00
Target Range22.00 - 22.00
Volume958.34K
Avg Volume1.22M
EPS Surprise-0.08
Investment DNA
How strong this company looks for long-term investors
29
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
20/100
Why this score▼
Manageable debt level · 0Healthy liquidity · 2.59Negative growth trendWeak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 8 analyst votes · 2026-09-05
100/100
Bullish
Bullish
8
Hold
0
Bearish
0
Price Target
2026-08-14
Low
$22.00
Mean
$22.00
Median
$22.00
High
$22.00
Insider Transactions
Recent executive and insider activity
Kenkare-Mitra Sara
Transaction: 05/14/2026
BUY
Change
+47,941
Price
Not reported
Filing
07/28/2026
Type
BUY
Kenkare-Mitra Sara
Transaction: 05/14/2026
BUY
Change
+84,200
Price
Not reported
Filing
05/21/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Laumas Sandeep | BUY | +47,941 | Not reported | 05/14/2026 | 07/28/2026 |
| Kenkare-Mitra Sara | BUY | +47,941 | Not reported | 05/14/2026 | 07/28/2026 |
| Kenkare-Mitra Sara | BUY | +84,200 | Not reported | 05/14/2026 | 05/21/2026 |
| Gupta Shalabh K. | BUY | +762,200 | Not reported | 05/14/2026 | 05/21/2026 |
| Townsend John | BUY | +169,500 | Not reported | 05/14/2026 | 05/20/2026 |
| Gupta Pramod | BUY | +169,500 | Not reported | 05/14/2026 | 05/20/2026 |
| Jermasek Douglas | BUY | +169,500 | Not reported | 05/14/2026 | 05/20/2026 |
| Laumas Sandeep | BUY | +84,200 | Not reported | 05/14/2026 | 05/18/2026 |
| Aggarwal Gaurav | SELL | — | $4.90 | 08/25/2025 | 08/26/2025 |
| Aggarwal Gaurav | BUY | +652,900 | Not reported | 08/25/2025 | 08/26/2025 |
| Jermasek Douglas | BUY | +10,000 | $4.71 | 07/28/2025 | 07/30/2025 |
| Gupta Pramod | BUY | +90,000 | $4.71 | 07/28/2025 | 07/30/2025 |
| Townsend John | BUY | +10,000 | $4.71 | 07/28/2025 | 07/30/2025 |
| Gupta Shalabh K. | BUY | +325,000 | $4.71 | 07/28/2025 | 07/30/2025 |
| Kenkare-Mitra Sara | BUY | +21,200 | $4.71 | 07/28/2025 | 07/30/2025 |
| Laumas Sandeep | BUY | +21,200 | $4.71 | 07/28/2025 | 07/30/2025 |
| Aggarwal Gaurav | BUY | +21,200 | $4.71 | 07/28/2025 | 07/30/2025 |
| Aggarwal Gaurav | SELL | -686 | $0.49 | 02/18/2025 | 02/19/2025 |
| Aggarwal Gaurav | BUY | +1,400,000 | Not reported | 02/18/2025 | 02/19/2025 |
| Aggarwal Gaurav | SELL | -2,695 | $0.49 | 10/09/2024 | 10/10/2024 |